JP2021020891A - Magnesium salt composition and production method thereof - Google Patents
Magnesium salt composition and production method thereof Download PDFInfo
- Publication number
- JP2021020891A JP2021020891A JP2020116029A JP2020116029A JP2021020891A JP 2021020891 A JP2021020891 A JP 2021020891A JP 2020116029 A JP2020116029 A JP 2020116029A JP 2020116029 A JP2020116029 A JP 2020116029A JP 2021020891 A JP2021020891 A JP 2021020891A
- Authority
- JP
- Japan
- Prior art keywords
- magnesium
- salt composition
- treating
- magnesium salt
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
本発明は、人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物及びその製造方法に関する。 The present invention relates to a magnesium salt composition for treating a human disease or as a bactericidal agent and a method for producing the same.
海水中には、塩化ナトリウムの他にマグネシウム塩等が含まれており、従来は、組成物をそれぞれに分解して研究してきた。 In addition to sodium chloride, magnesium salts and the like are contained in seawater, and conventionally, the compositions have been decomposed and studied.
しかしながら、発明者は、組成物その物が、当たり前ではあるが、不思議な効果を有することを見出した。海岸から離れたところでも鉄管が良く錆びる。震災で津波被害を受けた田畑の作物が、塩抜きをしないと育たない。等々の言わばナトリウム塩分を覆って見えなくする作用が現実にある。また、飛沫感染のウィルスが、武漢の方から雨に乗って香川県を渡り兵庫県及び日本全国に降っているが、ウィルス感染者が淡路島、小豆島、佐渡島には出ていない。また、遠く離れた南太平洋の島国にもウィルスの雨が降っているが、感染者が居ない。このことは、塩化ナトリウムの次に多いマグネシウム塩組成物そのものがウィルス感染症に効果があると見ることができる。 However, the inventor has found that the composition itself has, of course, a mysterious effect. Iron pipes often rust even away from the coast. The crops in the fields damaged by the tsunami caused by the earthquake will not grow unless salt is removed. In reality, it has the effect of covering the sodium salt and making it invisible. In addition, a droplet-infected virus has spread from Wuhan across Kagawa prefecture to Hyogo prefecture and all over Japan, but no virus-infected person has appeared on Awaji Island, Shodoshima Island, or Sado Island. The virus is also raining in the remote South Pacific island nations, but no one is infected. From this, it can be seen that the magnesium salt composition itself, which is the second most abundant after sodium chloride, is effective against viral infections.
本発明は、ウィルス性の風邪等の人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物及びその製造方法を提供する。 The present invention provides a magnesium salt composition for treating a human illness such as a viral cold or as a bactericide and a method for producing the same.
発明者は、鋭意研究の結果、なんと、塩化マグネシウムと硫酸マグネシウムとを含有するマグネシウム塩組成物が、ウィルス性の風邪等の人の病気を治療するため又は殺菌剤として効果があることを見出し、ウィルス性の風邪等の人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物及びその製造方法の発明を完成させたものである。 As a result of diligent research, the inventor found that a magnesium salt composition containing magnesium chloride and magnesium sulfate is effective for treating human diseases such as viral colds or as a bactericidal agent. This is a complete invention of a magnesium salt composition as a bactericidal agent and a method for producing the magnesium salt composition for treating a human disease such as a viral cold.
本発明は、次の内容によるものである。 The present invention is based on the following contents.
塩化マグネシウムと硫酸マグネシウムとを含有する人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物であって、塩化マグネシウムと硫酸マグネシウムとの重量比は１．０：０．２〜０．９である。 A magnesium salt composition for treating a person's disease containing magnesium chloride and magnesium sulfate or as a bactericidal agent, in which the weight ratio of magnesium chloride to magnesium sulfate is 1.0: 0.2 to 0.9. Is.
人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物の製造方法は、例えば、水に塩化マグネシウムと硫酸マグネシウムを重量比が１．０：０．２〜０．９の割合になるように加えた後、溶解させ又はカプセルに詰めたりする。 A method for producing a magnesium salt composition for treating a human disease or as a bactericide is, for example, to add magnesium chloride and magnesium sulfate to water in a weight ratio of 1.0: 0.2 to 0.9. After addition to, dissolve or encapsulate.
本発明のマグネシウム塩組成物を飲用することにより、ウィルス性の風邪等の人の病気の症状が改善し、病気を治療することができ、また、殺菌剤として使用することもできる。 By drinking the magnesium salt composition of the present invention, the symptoms of human illness such as a viral cold can be improved, the illness can be treated, and it can also be used as a bactericide.
以下、本発明の実施の形態の例について説明する。尚、本発明は、以下の形態の例に限定されるものではない。 Hereinafter, examples of embodiments of the present invention will be described. The present invention is not limited to the following examples.
本発明の人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物は、一例として、４種類のマグネシウム塩を適宜の比率に使用して製造する。前記比率は、重量比として、塩化マグネシウムと硫酸マグネシウムの重量比が１．０：０．２〜０．９の割合となるようにする。 The magnesium salt composition for treating a human disease or as a bactericide of the present invention is produced, for example, by using four kinds of magnesium salts in an appropriate ratio. As the weight ratio, the weight ratio of magnesium chloride and magnesium sulfate is 1.0: 0.2 to 0.9.
本発明の人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物の原料は、無水塩化マグネシウム、塩化マグネシウム六水和物、無水硫酸マグネシウム、硫酸マグネシウム七水和物等のマグネシウム塩を使用する。前記マグネシウム塩は、一般に入手できる市販品を使うことができる。 As the raw material of the magnesium salt composition for treating a human disease of the present invention or as a bactericidal agent, magnesium salts such as anhydrous magnesium chloride, magnesium chloride hexahydrate, anhydrous magnesium sulfate, and magnesium sulfate heptahydrate are used. To do. As the magnesium salt, a commercially available product that is generally available can be used.
本発明の人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物には、カルシウム塩、カリウム塩、酸化チタン、三二酸化鉄、臭化物、等を含まない。 The magnesium salt composition for treating human illness or as a bactericidal agent of the present invention does not contain calcium salt, potassium salt, titanium oxide, iron sesquioxide, bromide and the like.
本発明の人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物の形状は、特に限定はなく、人の病気を治療するために用いる場合は、水溶剤、カプセル剤、顆粒剤、錠剤等、飲用に適した形状とするのが好ましい。顆粒剤、カプセル剤、錠剤等に成型等するために必要な原料は、一般的に使用されるものを用いることができる。 The shape of the magnesium salt composition for treating a human disease or as a bactericidal agent of the present invention is not particularly limited, and when used for treating a human disease, a water solvent, a capsule, a granule, a tablet It is preferable that the shape is suitable for drinking. As the raw materials required for molding into granules, capsules, tablets and the like, commonly used raw materials can be used.
本発明を殺菌剤として用いる場合は、その用途によって、好ましい形状にすればよく、水溶剤とすることにより、より多くの用途で利用することが可能となる。 When the present invention is used as a bactericidal agent, it may have a preferable shape depending on its use, and by using an aqueous solvent, it can be used for more purposes.
本発明の人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物の製造方法は、水に塩化マグネシウムと硫酸マグネシウムを重量比が１．０：０．２〜０．９の割合になるように加え、それぞれの剤形として製造するが、カルシウム塩、カリウム塩、酸化チタン、三二酸化鉄、臭化物、等を含まないことを確認する。 In the method for producing a magnesium salt composition for treating a human disease or as a bactericidal agent of the present invention, the weight ratio of magnesium chloride and magnesium sulfate to water is 1.0: 0.2 to 0.9. In addition, it is produced as each dosage form, but it is confirmed that it does not contain calcium salt, potassium salt, titanium oxide, iron sesquioxide, bromide, etc.
次に人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物の実施例について説明する。 Next, examples of magnesium salt compositions for treating human diseases or as fungicides will be described.
実施例には、水１０００ｍｌ中に塩化マグネシウム六水和物３．５ｇと無水硫酸マグネシウム１．０ｇを加えて、攪拌して溶解させたマグネシウム塩組成物を製造し、用いた。その場合、塩化マグネシウムと硫酸マグネシウムとの重量比は１．０：０．６４相当となる。 In Examples, 3.5 g of magnesium chloride hexahydrate and 1.0 g of anhydrous magnesium sulfate were added to 1000 ml of water to prepare and dissolve a magnesium salt composition, which was used. In that case, the weight ratio of magnesium chloride and magnesium sulfate is equivalent to 1.0: 0.64.
被験者は、Ｈ２ブロッカー薬の副作用が出て「胃粘膜から胃酸が出ない無酸症」に罹って腸間膜炎のウィルス性の風邪症状が出た、発明者本人（９２才、男性）とした。 The subjects were the inventor (92 years old, male) who had the side effect of H2 blocker drug and suffered from "achlorhydria in which gastric acid does not come out from the gastric mucosa" and had viral cold symptoms of mesenteritis. did.
被験者は、前記マグネシウム塩組成物を食間に１日３回、１回当たり５０ｍｌ、２８日服用した。1日に服用したマグネシウムの総量は、１８６．１ｍｇである。 The subject took the magnesium salt composition three times a day between meals at 50 ml for 28 days. The total amount of magnesium taken daily is 186.1 mg.
その結果、被験者は、咳、痰の症状が緩和し、微熱が下がり、大腸の調子がよくなり、便秘が解消した。更に、胃痛、胃の膨満感、げっぷなどの症状も改善した。特に、補聴器の聞こえが良くなり、ドライアイ気味の眼が正常になった。 As a result, the subject's cough and sputum symptoms were alleviated, low-grade fever decreased, the large intestine became better, and constipation disappeared. In addition, symptoms such as stomach pain, bloating, and belching improved. In particular, hearing aids became better and dry eyes became normal.
以上のとおり、人の病気を治療するため又は殺菌剤としてのマグネシウム塩組成物は、ウィルス性の風邪の症状の回復に著しい効果が認められ、味覚神経、嗅覚神経、聴覚神経、視覚神経にも効果があると考えられる。
As described above, the magnesium salt composition for treating human illness or as a bactericidal agent has been found to have a remarkable effect on the recovery of the symptoms of a viral cold, and also on the taste nerve, olfactory nerve, auditory nerve, and visual nerve. It is considered to be effective.
Claims (2)
Magnesium chloride and magnesium sulphate are added to water in a weight ratio of 1.0: 0.2 to 0.9 and then dissolved or encapsulated to treat human illness or sterilize. A method for producing a magnesium salt composition as an agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020116029A JP2021020891A (en) | 2020-07-04 | 2020-07-04 | Magnesium salt composition and production method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020116029A JP2021020891A (en) | 2020-07-04 | 2020-07-04 | Magnesium salt composition and production method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2021020891A true JP2021020891A (en) | 2021-02-18 |
Family
ID=74574330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020116029A Pending JP2021020891A (en) | 2020-07-04 | 2020-07-04 | Magnesium salt composition and production method thereof |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2021020891A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533047A (en) * | 2001-06-07 | 2005-11-04 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for prevention and treatment of after ulcers and herpes simplex lesions |
| JP2007015983A (en) * | 2005-07-08 | 2007-01-25 | Noevir Co Ltd | Agent for controlling balance of ecosystem of indigenous bacterium in skin |
| JP2007513162A (en) * | 2003-12-04 | 2007-05-24 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for topical treatment of skin infections |
| JP2009051757A (en) * | 2007-08-24 | 2009-03-12 | Isao Moriya | Method for utilizing magnesium chloride for disease of creature such as cow, chicken and pig |
| JP2011016736A (en) * | 2009-07-07 | 2011-01-27 | Lion Corp | Oral liquid composition |
| CN103830271A (en) * | 2014-02-22 | 2014-06-04 | 武汉药谷生物工程有限公司 | Disinfectant composition and application thereof |
-
2020
- 2020-07-04 JP JP2020116029A patent/JP2021020891A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005533047A (en) * | 2001-06-07 | 2005-11-04 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for prevention and treatment of after ulcers and herpes simplex lesions |
| JP2007513162A (en) * | 2003-12-04 | 2007-05-24 | チョウ・コンサルティング・インコーポレイテッド | Compositions and methods for topical treatment of skin infections |
| JP2007015983A (en) * | 2005-07-08 | 2007-01-25 | Noevir Co Ltd | Agent for controlling balance of ecosystem of indigenous bacterium in skin |
| JP2009051757A (en) * | 2007-08-24 | 2009-03-12 | Isao Moriya | Method for utilizing magnesium chloride for disease of creature such as cow, chicken and pig |
| JP2011016736A (en) * | 2009-07-07 | 2011-01-27 | Lion Corp | Oral liquid composition |
| CN103830271A (en) * | 2014-02-22 | 2014-06-04 | 武汉药谷生物工程有限公司 | Disinfectant composition and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| ACS APPLIED MATERIALS & INTERFACES, vol. 5, no. 3, JPN6020039977, 2013, pages 1137 - 1142, ISSN: 0004368853 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7424684B2 (en) | Chinese herbal medicine complex prescription with lung purifying and detoxifying function and its application | |
| JPWO2013073644A1 (en) | Complex health functional food containing many kinds of minerals | |
| Lewis et al. | Zinc gluconate: acute ingestion | |
| CN104127667B (en) | It is a kind of to treat pharmaceutical composition of chronic pharyngitis and preparation method thereof | |
| US20170080024A1 (en) | Effervescent gargle tablet and method of using same | |
| CN107789654A (en) | Discharge the air freshener of element anion | |
| NO814337L (en) | PROCEDURE AND PREPARATION FOR THE TREATMENT OF DISEASE, SPECIFIC ART | |
| JP2021020891A (en) | Magnesium salt composition and production method thereof | |
| CN110996941A (en) | Compositions and therapeutic procedures for treating pathogen infections | |
| Sahu et al. | Cow urine-Therapeutic value | |
| CN108420905B (en) | Camellia oleifera for preventing and treating stomatitis and pharyngitis and preparation method thereof | |
| CN102960874A (en) | Mask for protecting immunity | |
| JP2021172643A (en) | Iodine-based liquid preparation and method for producing the same | |
| JP2021176834A (en) | Magnesium salt composition obtained by mixing magnesium chloride and magnesium sulfate in fixed ratio range, and production method thereof | |
| JP5070047B2 (en) | Gastrointestinal composition | |
| CN106860476A (en) | A kind of new pharmaceutical preparation Colloidal Bismuth Tartrate particle | |
| KR20140098037A (en) | Artificial spa composition for baths and the manufacturing method | |
| RU2619736C2 (en) | Capsules for complex treatment of urinary system diseases | |
| JP2023133314A (en) | Combined compound consisting of magnesium chloride and magnesium sulfate | |
| BE1030314B1 (en) | Antiviral composition based on calcium hydroxide solution | |
| JP4435427B2 (en) | Formulation for bowel function adjustment | |
| Marselos et al. | Inorganic Ingredients in Aelius Promotus’ Dynameron-Relevance to Current Scientific Data | |
| CN107595868B (en) | Application of the desgalactotigonin in preparation treatment bronchitis drug | |
| WO2013159140A1 (en) | Eds005 skin cancer cream | |
| Kühni et al. | Colloidal Silver: The Natural Antibiotic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200715 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200822 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20200822 |
|
| A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20200916 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201021 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210409 |